Merck: presents data for lung cancer
(CercleFinance.com) - Merck has announced five-year data for KEYTRUDA (pembrolizumab) plus chemotherapy.
The data showed a sustained survival benefit over chemotherapy alone in two studies in metastatic non-small cell lung cancer (NSCLC).
The five-year overall survival rate was 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively.
In first-line metastatic non-small cell lung cancer, KEYTRUDA-based regimens have now shown a five-year survival advantage in four trials.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The data showed a sustained survival benefit over chemotherapy alone in two studies in metastatic non-small cell lung cancer (NSCLC).
The five-year overall survival rate was 19.4% and 18.4% for KEYTRUDA plus chemotherapy in KEYNOTE-189 and KEYNOTE-407, respectively.
In first-line metastatic non-small cell lung cancer, KEYTRUDA-based regimens have now shown a five-year survival advantage in four trials.
Copyright (c) 2022 CercleFinance.com. All rights reserved.